Traduction de «Diffusion effect » (Anglais → Français) :

diffusion effect [ diffusion | soft focus effect | soft focus ]

thermodiffusion [ thermal diffusion | Soret effect | Soret transport effect | Soret action | thermodiffusive transport | thermotransport ]

Modifiers The following fourth-character subdivisions classify morphological changes and are for use with categories N00-N07. Subdivisions .0-.8 should not normally be used unless these have been specifically identified (e.g. by renal biopsy or autopsy). The three-character categories relate to clinical syndromes. Code Title .0 Minor glomerular abnormality Minimal change lesion .1 Focal and segmental glomerular lesions Focal and segmental:hyalinosis | sclerosis | Focal glomerulonephritis .2 Diffuse membranous glomerulonephritis .3 Diffuse mesangial proliferative glomerulonephritis .4 Diffuse endocapillary proliferative glomerulonephritis ...[+++] .5 Diffuse mesangiocapillary glomerulonephritis Membranoproliferative glomerulonephritis, types 1 and 3, or NOS .6 Dense deposit disease Membranoproliferative glomerulonephritis, type 2 .7 Diffuse crescentic glomerulonephritis Extracapillary glomerulonephritis .8 Other Proliferative glomerulonephritis NOS .9 Unspecified | Minimal change lesion | Focal and segmental:hyalinosis | sclerosis | Focal glomerulonephritis | Membranoproliferative glomerulonephritis, types 1 and 3, or NOS | Membranoproliferative glomerulonephritis, type 2 | Extracapillary glomerulonephritis | Proliferative glomerulonephritis NOS

effective diffusion constant

effective diffusion-coefficient

pulmonary diffusing capacity [ DL | diffusing capacity | diffusion capacity | diffusing capacity of the lung | diffusing capacity of the lungs | lung diffusing capacity ]

Blast effects Exposure to ionizing radiation from nuclear weapon Fireball effects Heat Other direct and secondary effects of nuclear weapons

Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include self-report data, analysis of blood and other body fluids, characteristic physical and psychological symptom ...[+++]s, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9). Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used. | Modifiers The following fourth-character subdivisions are for use with categories F10-F19: Code Title .0 Acute intoxication A condition that follows the administration of a psychoactive substance resulting in disturbances in level of consciousness, cognition, perception, affect or behaviour, o ...

diffused detector | diffused junction counter | diffused junction detector

6. The ex ante evaluation shall assess proportionality of the envisaged intervention with regard to the size of the identified funding gap, the expected leverage effect of the planned financial instrument and also examine additional qualitative effects, such as the diffusion of best practices, the effective promotion of Union policy objectives throughout the implementation chain or the access to specific expertise available from actors involved in the implementation chain.

These demonstration projects could benefit from joint programming and EU-wide participation, to reach the minimum effective size for diffusion of these technologies.

Their effectiveness contributes to a better assimilation of knowledge and diffusion of innovation throughout the Union.

76. Recalls that, through water bills, EU citizens are bearing the cost of purification of water and water treatment, and stresses that enacting policies that effectively combine and reconcile water resource protection objectives with cost savings, such as ‘control at source’ approaches, are more efficient and financially preferable; recalls that according to the EEA’s 2015 report on the state of the environment, more than 40 % of rivers and coastal waters are affected by diffuse pollution caused by agriculture, while between 20 % an ...[+++]d 25 % are subjected to pollution deriving from point sources such as industrial structures, sewage systems and wastewater management networks; highlights the importance of effective implementation of the WFD and the Drinking Water Directive, better coordination as regards their implementation, more coherence when drafting legislation and more proactive measures for saving water resources and substantially increasing water use efficiency across all sectors (industries, households, agriculture, distribution networks); recalls that ensuring sustainable protection of natural areas such as freshwater ecosystems is also key to development and crucial for providing drinking water supplies, and reduces costs for citizens and operators;